Companion Animal Vaccines Market: Canine Segment Anticipated to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment, 2016-2026

Companion Animal Vaccines Market: Canine Segment Anticipated to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment, 2016-2026

Companion animal vaccines are used to stimulate an immune response in pets such as canine, avian and feline. These vaccine products are of various types such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines are derived from disease-causing pathogens such as virus or bacteria, which have been weakend under laboratory conditions. Conjugate vaccines are an antigen or toxoid-containing preparation that is linked to polysaccharides and stimulate the immature immune system to defend against the disease-causing organism. Inactivated vaccines are made from microorganisms such as viruses and bacteria that have been killed through physical or chemical processes. Subunit vaccines, like inactivated whole-cell vaccines, do not contain live components of the pathogen. Toxoid vaccines are based on the toxin produced by certain bacteria, which is rendered harmless and used as the antigen in the vaccine to elicit an immune response. DNA vaccines are manufactured by inserting DNA into a bacterial plasmid, which functions as the vector. Recombinant vaccines are produced by genetic engineering technology and use attenuated virus or bacterium as a vector to introduce microbial DNA to the cells of the body.

The global companion animal vaccines market was valued at more than US$ 2,100 Mn in 2015 and is projected to register a CAGR of 6.8% during the forecast period. The market is expected to be valued at nearly US$ 4,500 Mn by the end of 2026.

Global Companion Animal Vaccines Market Forecast, By Species Type, 2016–2026

The Canine species segment is anticipated to register a 6.9% CAGR over the forecast period and be valued at nearly US$ 2,500 Mn by 2026 end. The Canine species segment was estimated to account for 50.9% share of the global companion animal vaccines market by 2016 end. Whereas the Avian species segment was estimated to account for 14.1% value share of the global companion animal vaccines market by 2016 end.

Global Companion Animal Vaccines Market Attractiveness Analysis, By Species Type, 2016–2026

The Canine segment dominated the global companion animal vaccines market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. The Canine segment is the most attractive segment, recording an attractiveness index of 1.5 over the forecast period. The segment is projected to account for 51.0% value share by 2026 end. The Feline segment is expected to be the second most lucrative segment in the global companion animal vaccines market, with an attractiveness index of 1.1 during the forecast period.

Market consolidation in developed regions could ease product availability

Mergers and acquisitions are gaining a wider footprint within the global companion animal vaccines market in developed regions, which is expected to widen product availability and ease market access. For example, global veterinary product manufacturer Elanco has agreed to buy Boehringer Ingelheim Vetmedica Inc.’s U.S. companion animal vaccines business apart from Fort Dodge manufacturing facility as of October 2016. Besides strengthening Elanco’s market position in the global animal health business, the company also plans to boost vaccine research and testing in collaboration with veterinarians.

“Rising adoption of pets is fuelling the global companion animal vaccines market

Increasing humanisation of pets and adoption in developed markets such as the U.S. is driving the demand for animal vaccines. Furthermore, growing trend of using pets as a status symbol in many countries is also expected to fuel the market’s revenue growth. Pets are known to provide relief from psychological stress emanating from solitary nuclear family structures, prevalent across most developed and rapidly emerging markets. To exemplify, data from the American Pet Products Association noted that as of 2016, 70 million to 80 million dogs (approximately 37% to 47% of all households) and 74 million to 96 million cats (30% to 37% of all households) are owned in the U.S.”

-- Analyst – Healthcare, Pharmaceuticals and Medical Devices, Future Market Insights


1. Executive Summary
2. Market Introduction
2.1. Companion Animal Vaccines Market Definition
2.2. Companion Animal Vaccines Market Taxonomy
2.3. Veterinary Vaccines Market
3. Companion Animal Vaccines Market Analysis Scenario
3.1. Regulations and Reimbursement Scenario
3.2. Global Company Market Share Analysis (2015)
3.3. Mechanism for Veterinary Product Approval
3.4. Companion Animal Vaccines Market Overview
3.4.1. List of Active Participants
4. Companion Animal Vaccines Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Global Trends
5. Global Companion Animal Vaccines Market Analysis and Forecast, By Product Type
5.1. Introduction
5.1.1. Basis Point Share (BPS) Analysis By Product Type
5.1.2. Y-o-Y Growth Projections By Product Type
5.2. Market Size (US$ Mn) Forecast By Product Type
5.2.1. Attenuated Live Vaccines
5.2.2. Conjugate Vaccines
5.2.3. Inactivated Vaccines
5.2.4. Subunit Vaccines
5.2.5. Toxoid Vaccines
5.2.6. DNA Vaccines
5.2.7. Recombinant Vaccines
5.3. Market Attractiveness Analysis By Product Type
5.4. Prominent Trends
6. Global Companion Animal Vaccines Market Analysis and Forecast, By Distribution Channel
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis By Distribution Channel
6.1.2. Y-o-Y Growth Projections By Distribution Channel
6.1.3. Comparative Analysis By Distribution Channel
6.2. Market Size (US$ Mn) Forecast By Distribution Channel
6.2.1. Veterinary Clinics
6.2.2. Veterinary Hospitals
6.2.3. Veterinary Research Institutes
6.2.4. Retail Pharmacies & Others
6.3. Market Attractiveness Analysis By Distribution Channel
6.4. Prominent Trends
7. Global Companion Animal Vaccines Market Analysis and Forecast, By Species Type
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis By Species Type
7.1.2. Y-o-Y Growth Projections By Species Type
7.1.3. Comparative Analysis By Species Type
7.2. Market Size (US$ Mn) Forecast By Species Type
7.2.1. Canine
7.2.2. Avian
7.2.3. Feline
7.3. Market Attractiveness Analysis By Species Type
8. Global Companion Animal Vaccines Market Analysis and Forecast, By Region
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis By Region
8.1.2. Y-o-Y Growth Projections By Region
8.2. Market Size (US$ Mn) Forecast By Region
8.2.1. North America
8.2.2. Latin America
8.2.3. Western Europe
8.2.4. Eastern Europe
8.2.5. Asia Pacific Excl. Japan (APEJ)
8.2.6. Japan
8.2.7. Middle East and Africa (MEA)
8.3. Market Attractiveness Analysis By Region
9. North America Companion Animal Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.1.3. Key Regulations
9.2. Market Size (US$ Mn) Forecast By Country
9.2.1. U.S.
9.2.2. Canada
9.3. Market Size (US$ Mn) Forecast By Product Type
9.3.1. Attenuated Live Vaccines
9.3.2. Conjugate Vaccines
9.3.3. Inactivated Vaccines
9.3.4. Subunit Vaccines
9.3.5. Toxoid Vaccines
9.3.6. DNA Vaccines
9.3.7. Recombinant Vaccines
9.4. Market Size (US$ Mn) Forecast By Distribution Channel
9.4.1. Veterinary Clinics
9.4.2. Veterinary Hospitals
9.4.3. Veterinary Research Institutes
9.4.4. Retail Pharmacies & Others
9.5. Market Size (US$ Mn) Forecast By Species Type
9.5.1. Canine
9.5.2. Avian
9.5.3. Feline
9.6. Market Attractiveness Analysis
9.6.1. By Country
9.6.2. By Product Type
9.6.3. By Distribution Channel
9.6.4. By Species Type
10. Latin America Companion Animal Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.1.3. Key Regulations
10.2. Market Size (US$ Mn) and Volume (Units) Forecast By Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Market Size (US$ Mn) Forecast By Product Type
10.3.1. Attenuated Live Vaccines
10.3.2. Conjugate Vaccines
10.3.3. Inactivated Vaccines
10.3.4. Subunit Vaccines
10.3.5. Toxoid Vaccines
10.3.6. DNA Vaccines
10.3.7. Recombinant Vaccines
10.4. Market Size (US$ Mn) Forecast By Distribution Channel
10.4.1. Veterinary Clinics
10.4.2. Veterinary Hospitals
10.4.3. Veterinary Research Institutes
10.4.4. Retail Pharmacies & Others
10.5. Market Size (US$ Mn) Forecast By Species Type
10.5.1. Canine
10.5.2. Avian
10.5.3. Feline
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Product Type
10.6.3. By Distribution Channel
10.6.4. By Species Type
11. Western Europe Companion Animal Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country / Region
11.1.2. Y-o-Y Growth Projections By Country
11.1.3. Key Regulations
11.2. Market Size (US$ Mn) and Volume (Units) Forecast By Country / Region
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. Spain
11.2.5. U.K.
11.2.6. BENELUX
11.2.7. Rest of Western Europe
11.3. Market Size (US$ Mn) Forecast By Product Type
11.3.1. Attenuated Live Vaccines
11.3.2. Conjugate Vaccines
11.3.3. Inactivated Vaccines
11.3.4. Subunit Vaccines
11.3.5. Toxoid Vaccines
11.3.6. DNA Vaccines
11.3.7. Recombinant Vaccines
11.4. Market Size (US$ Mn) Forecast By Distribution Channel
11.4.1. Veterinary Clinics
11.4.2. Veterinary Hospitals
11.4.3. Veterinary Research Institutes
11.4.4. Retail Pharmacies & Others
11.5. Market Size (US$ Mn) Forecast By Species Type
11.5.1. Canine
11.5.2. Avian
11.5.3. Feline
11.6. Market Attractiveness Analysis
11.6.1. By Country
11.6.2. By Product Type
11.6.3. By Distribution Channel
11.6.4. By Species Type
12. Eastern Europe Companion Animal Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.1.3. Key Regulations
12.2. Market Size (US$ Mn) and Volume (Units) Forecast By Country
12.2.1. Russia
12.2.2. Poland
12.2.3. Rest of Eastern Europe
12.3. Market Size (US$ Mn) Forecast By Product Type
12.3.1. Attenuated Live Vaccines
12.3.2. Conjugate Vaccines
12.3.3. Inactivated Vaccines
12.3.4. Subunit Vaccines
12.3.5. Toxoid Vaccines
12.3.6. DNA Vaccines
12.3.7. Recombinant Vaccines
12.4. Market Size (US$ Mn) Forecast By Distribution Channel
12.4.1. Veterinary Clinics
12.4.2. Veterinary Hospitals
12.4.3. Veterinary Research Institutes
12.4.4. Retail Pharmacies & Others
12.5. Market Size (US$ Mn) Forecast By Species Type
12.5.1. Canine
12.5.2. Avian

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook